Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen Inc. | 0.95% | 176.30 | 1.2% | $600.82m | |
| GILD | Gilead Sciences, Inc. | 0.62% | 68.02 | 0.9% | $542.46m | |
| BIIB | Biogen Inc. | -0.06% | 280.40 | 1.2% | $519.30m | |
| CELG | Celgene Corporation | -2.01% | 78.37 | 1.2% | $513.71m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -2.01% | 301.81 | 2.6% | $316.79m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -0.07% | 121.07 | 2.0% | $253.26m | |
| ILMN | Illumina, Inc. | 0.45% | 269.67 | 3.5% | $244.32m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.58% | 157.24 | 1.9% | $236.54m | |
| NKTR | Nektar Therapeutics | 7.66% | 85.30 | 6.0% | $212.18m | |
| A | Agilent Technologies, Inc. | 1.15% | 64.32 | 1.5% | $199.05m | |
| INCY | Incyte Corporation | 1.79% | 67.83 | 2.5% | $194.51m | |
| SRPT | Sarepta Therapeutics, Inc. | 1.78% | 93.48 | 16.6% | $131.29m | |
| EXAS | Exact Sciences Corporation | 2.43% | 52.36 | 25.5% | $116.06m | |
| BMRN | BioMarin Pharmaceutical Inc. | 0.51% | 88.88 | 4.4% | $114.43m | |
| ALNY | Alnylam Pharmaceuticals, Inc | 1.15% | 102.81 | 9.8% | $103.66m |
Company Profile
Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin on December 3, 2014 and is headquartered in Abingdon, the United Kingdom.